1515
Annons
EMPLICURE RECEIVES FORMAL NOTIFICATION OF APPROVED US PATENT FOR INHALATION OF PHARMACEUTICALS

Emplicure AB has received issue notification from the US Patent and Trademark Office that a formal approval of the inhalation platform of pharmaceuticals will be issued on December 21, 2021.

EMPLICURE RECEIVES FORMAL NOTIFICATION OF APPROVED US PATENT FOR INHALATION OF PHARMACEUTICALS

Emplicure AB has received issue notification from the US Patent and Trademark Office that a formal approval of the inhalation platform of pharmaceuticals will be issued on December 21, 2021.

"The United States is an important market for us. The announcement of patent approval for inhaled drugs is extremely gratifying and important, as it strengthens our conditions to develop new unique and patent-protected pharmaceutical products for inhalation", says Torbjörn W. Larsson, CEO of Emplicure.

The patent, U.S. Patent No. 11,202,871 will be valid into 2037. The information about the preliminary approval was published August 19, 2021.

Adviser

Certified Adviser is Mangold Fondkommission AB, +46 8 503 015 50, or via ca@mangold.se

For more information, please contact:

Torbjörn W. Larsson
CEO
Phone: +46 (0)70 747 65 99
Email: twl@emplicure.com

Anna-Lena Nicolson
CFO, Investor Relations
Phone: +46 (0)72 33 68 68
Email: aln@emplicure.com

The following documents can be retrieved from beQuoted
PM-Emplicure-receives-formal-approval-of-US-patent-for-inhal.pdf

Emplicure is a pharmaceutical company developing new and innovative drugs by combining existing and approved active substances, and advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain, and with abuse deterrent formulations. The wholly owned subisidiary, Amplicon AB develops consumer products, with tobacco-free nicotine as the first product. Read more at www.emplicure.com

Source: beQuoted
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

spara
1090kr
Prenumerera